Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,362 JPY | +2.16% | +9.20% | -0.38% |
29/03 | Nakanishi to Sell 8.49 Million Yen Worth of Shares As Restricted Stock Compensation | MT |
19/03 | Nakanishi to Cancel 841,200 Repurchased Shares on April 5 | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company is highly valued given the cash flows generated by its activity.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-0.38% | 1.27B | - | ||
+11.84% | 27.79B | B+ | ||
-32.98% | 2.98B | B- | ||
-15.97% | 2.52B | C+ | ||
+11.90% | 2.34B | - | A- | |
-1.11% | 1.91B | B | ||
-7.78% | 1.39B | B | ||
+4.01% | 1.13B | - | ||
+13.51% | 1.12B | C | ||
-2.06% | 1.02B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 7716 Stock
- Ratings Nakanishi Inc.